The family of a Louisiana woman who died after uncontrolled bleeding allegedly linked to the anticoagulant medication Xarelto have joined thousands of plaintiffs filing litigation against Johnson & Johnson unit Janssen Pharmaceuticals and Bayer over side effects associated with the drug.
Among other allegations, the lawsuit claims that the woman suffered serious side effects, including life threatening bleeding, anemia, sepsis, and kidney failure prior to her death on January 14, 2016.
What is Xarelto?
Xarelto is a type of blood thinner known as a factor Xa inhibitor. It was approved by the U.S. Food and Drug Administration (FDA) in 2011, and is currently being prescribed to prevent strokes in people with atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.
While all blood thinners increase the risk of bleeding problems, Xarelto has been linked to an increased number of uncontrollable blood injuries, primarily because there is no approved antidote available for patients who use the medication, and many of the side effects have been severe because the bleeding cannot be effectively controlled.
Xarelto Cases Make Similar Claims
U.S. District Judge Eldon Fallon is overseeing multidistrict litigation (MDL) in Louisiana federal district court, where approximately 14,000 Xarelto cases are currently pending. These Xarelto claims make similar allegations against J&J and Bayer, including that the companies:
• Failed to warn consumers about the absence of an appropriate reversal agent for the medication.
• Were negligent in promoting the safety, efficacy, and convenience of the product.
• Hid known dangerous side effects associated with Xarelto use from the public.
• Undertook unreasonable risks, intentionally, and with reckless disregard to the life and safety of the general public.